Alzheimer’s Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense

Despite scant evidence that it works, the drug, Aduhelm, is predicted to generate billions of dollars in revenue, much of it from Medicare.Despite scant evidence that it works, the drug, Aduhelm, is predicted to generate billions of dollars in revenue, much of it from Medicare.Drugs (Pharmaceuticals), Alzheimer’s Disease, Health Insurance and Managed Care, Clinical Trials, Biogen IncRead More